By Katherine Hamilton
Tenon Medical shares jumped fourfold after the company said it gained clearance from the Food and Drug Administration for a joint-disease treatment.
Shares quadrupled to $3.96 on Tuesday, regaining Tenon's losses since mid-October. The stock is still down 47% over the past 12 months.
The medical device company said Monday the FDA had cleared Catamaran for expanded use in augmenting thoracolumbar fusion. That means Catamaran can now treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.
"This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market," Chief Technology Officer and co-founder Ricahrd Ginn said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 25, 2025 11:59 ET (15:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。